By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Revance Therapeutics, Inc. 

7555 Gateway Boulevard

Newark  California  94560  U.S.A.
Phone: 510-742-3400 Fax: 510-742-3401


Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.

Key Statistics

Ownership: Public

Web Site: Revance
Employees: 100+
Symbol: RVNC

Company News
Revance (RVNC) Appoints Mark Foley To Its Board Of Directors 9/6/2017 6:22:38 AM
Revance (RVNC) Releases Second Quarter 2017 Results 8/4/2017 7:54:50 AM
Revance (RVNC) Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer And President, Aesthetics & Therapeutics 8/2/2017 7:01:12 AM
Revance (RVNC) To Release Second Quarter 2017 Financial Results Thursday, August 3, 2017 7/25/2017 10:13:50 AM
Revance (RVNC) Release: Positive BELMONT Phase II Trial Results Published In Dermatologic Surgery 6/15/2017 7:59:31 AM
Revance (RVNC) Reports Additional Positive Week 24 Efficacy Results From RT002 Injectable Phase II Cervical Dystonia Trial 6/6/2017 8:03:39 AM
Revance (RVNC) Announces Positive Top-Line 24-Week Duration Of Effect Results In All Three Cohorts In RT002 Injectable Phase II Cervical Dystonia Trial 5/19/2017 6:43:54 AM
Revance (RVNC) Releases First Quarter 2017 Results 5/10/2017 7:14:59 AM
Revance (RVNC) Provides Update On Phase II Program For RT002 Injectable In The Management Of Plantar Fasciitis 5/1/2017 6:06:07 AM
Revance (RVNC) To Release First Quarter 2017 Financial Results Tuesday, May 9, 2017 4/26/2017 7:06:33 AM